3750
ADR Biomedical Holdings Inc.
ＡＤＲバイオメディカルホールディングス
- Industry
- Information & Communication
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
1,335,578
Mar 2023
2,144,712
Mar 2024
1,560,388
Mar 2025
122,204
Mar 2026
50,988
Operating profit(thousand JPY)
Mar 2022
-462,323
Mar 2023
-794,359
Mar 2024
-772,742
Mar 2025
-806,888
Mar 2026
-906,175
Operating profit margin(%)
Mar 2022
-34.62
Mar 2023
-37.04
Mar 2024
-49.52
Mar 2025
-660.28
Mar 2026
-1,777.23
Profit before tax(thousand JPY)
Mar 2022
-65,336
Mar 2023
-1,166,076
Mar 2024
-1,011,213
Mar 2025
-2,152,797
Mar 2026
-397,853
Profit(thousand JPY)
Mar 2022
-77,633
Mar 2023
-1,059,941
Mar 2024
138,155
Mar 2025
-2,140,086
Mar 2026
-396,904
Total assets(thousand JPY)
Mar 2022
16,006,766
Mar 2023
14,091,635
Mar 2024
5,816,334
Mar 2025
3,537,592
Mar 2026
368,058
Cash and cash equivalents(thousand JPY)
Mar 2022
701,558
Mar 2023
673,050
Mar 2024
1,038,227
Mar 2025
255,980
Mar 2026
125,901
Cash flows from operating activities(thousand JPY)
Mar 2022
-187,784
Mar 2023
-39,518
Mar 2024
-1,152,230
Mar 2025
-987,038
Mar 2026
-784,773
Cash flows from investing activities(thousand JPY)
Mar 2022
-216,193
Mar 2023
-283,065
Mar 2024
8,689,978
Mar 2025
22,901
Mar 2026
2,979,364
Cash flows from financing activities(thousand JPY)
Mar 2022
35,797
Mar 2023
294,227
Mar 2024
-7,172,572
Mar 2025
171,650
Mar 2026
-2,321,675
Return on equity(%)
Mar 2022
-2.3
Mar 2023
-35.6
Mar 2024
5.5
Mar 2025
-142.8
Mar 2026
-180
Equity ratio(%)
Mar 2022
21.9
Mar 2023
17.3
Mar 2024
44.3
Mar 2025
11.8
Mar 2026
6
Earnings per share(JPY per share)
Mar 2022
-8.79
Mar 2023
-118.71
Mar 2024
15.47
Mar 2025
-239.7
Mar 2026
-44.46
Net assets per share(JPY per share)
Mar 2022
392.12
Mar 2023
273.41
Mar 2024
288.89
Mar 2025
46.93
Mar 2026
2.47
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.